Patient characteristics
| Parameter | N (%) | Median (range) |
| All patients | 130 (100) | |
| Age at diagnosis (years) | 66 (24–91) | |
| Menopausal status | ||
| Pre-/peri-menopausal | 15 (11.5) | |
| Post-menopausal | 115 (88.5) | |
| ECOG performance status | ||
| ECOG 0–1 | 97 (75.2) | |
| ECOG ≥2 | 32 (24.8) | |
| BMI (kg/m2) | 23 (17–53) | |
| CA125 at diagnosis (kU/l) | 736 (25–26 296) | |
| Histologic subtype | ||
| High-grade serous | 116 (89.2) | |
| Mucinous | 4 (3.1) | |
| Other | 7 (5.4) | |
| Unknown | 3 (2.3) | |
| FIGO stage | ||
| I/II | 9 (6.9) | |
| IIIA/B | 5 (3.8) | |
| IIIC | 89 (68.5) | |
| IVA | 10 (7.7) | |
| IVB | 17 (13.1) | |
| Indication for neoadjuvant chemotherapy | ||
| Advanced FIGO stage | 119 (91.5) | |
| Comorbidities | 5 (3.8) | |
| Thromboembolic event | 2 (1.5) | |
| Other | 4 (3.1) | |
| Number of neoadjuvant chemotherapy cycles | ||
| 2 to 4 | 113 (86.9) | |
| >4 | 17 (13.1) | |
BMI, body mass index; CA125, cancer antigen 125; ECOG, Eastern Cooperative Oncology Group performance status; FIGO, International Federation of Gynecology and Obstetrics.